Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Wendys Co — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B), while Wendys Co trades at $6.46 (market cap $1.23B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 4.1× Wendys Co's market cap, and Wendys Co pays a 4.35% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Wendys Co for 78 Days on average.
| TVTX | WEN | |
|---|---|---|
Market Cap | $5.02B | $1.23B |
Volume | 2,060,842 | 6,130,931 |
Sector | Health | Consumer Cyclical |
52-Week High | $67.52 | $9.33 |
52-Week Low | $26.79 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $5.15B | $4.96B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Wendy's (WEN) trades at $6.35, up 0.63% with a bearish technical outlook. The stock shows attractive valuation metrics with a P/E of 9.62 and P/S of 0.55, but faces fundamental challenges including declining net income margins (5.72% in 2026) and high debt levels. Recent news highlights franchisee bankruptcies and competitive pressures, though the company has beaten earnings expectations for three consecutive quarters. Analyst consensus remains cautious with a $7.58 price target and 64.71% hold rating.
The investment case balances deep value against operational headwinds. While valuation appears compelling, declining profitability, franchisee instability, and intense competition create significant risks. The stock offers a dividend yield but requires successful execution under new leadership to reverse negative trends. Near-term catalysts include Q3 2026 earnings and management's turnaround strategy implementation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
